Breast surgery

---

NIHR Portfolio Studies​ - Open to recruitment:

ATNEC Breast Cancer Study  
Principal Investigator: Mr Tahir Masudi
Sponsor: University Hospitals of Derby and Burton NHS Foundation Trust
Randomised trial evaluating axillary treatment post-neoadjuvant chemo in patients with no residual disease on sentinel node biopsy.

---

---

EndoNET
Principal Investigator: Miss Bertha In T'hout
Sponsor: University of Oxford
This trial is evaluating the effectiveness of neoadjuvant endocrine treatment in post-menopausal women

---

nihr portfolio studies - In Follow-up:

MAMMO-50: Mammographic surveillance in breast cancer patients aged 50 years or older
Principal Investigator: Mr Tahir Masudi
Sponsor: University of Warwick
​Mammo-50 is a multi-centre, randomised, controlled, phase III trial of annual mammography versus 2-yearly for conservation surgery patients or 3-yearly for mastectomy patients.​
​

PERSEPHONE: A phase III, randomised trial comparing six months Herceptin® treatment with twelve months, in patients with early stage breast cancer
Principal Investigator: Mr Tahir Masudi
Sponsor: Cambridge University Hospitals NHS Foundation Trust
To compare 6 months Trastuzumab therapy with the standard 12 months therapy in terms of disease free survival in patients with HER 2 positive early stage breast cancer. We also aim to analyse Health Economic and quality of life data for superiority for 6 months Trastuzumab as well as assess cardiac function for development of cardiac damage.​

POSNOC: POsitive Sentinel NOde: adjuvant therapy alone versus adjuvant therapy plus Clearance or axillary radiotherapy
Principal Investigator: Mr Tahir Masudi
Sponsor: University Hospitals of Derby and Burton NHS Foundation Trust
​​The POSNOC International trial is comparing two ways of treating breast cancer which has spread to the armpit.
​​

Add-Aspirin
Principal Investigator: Mr Tahir Masudi
Sponsor: University College London
Add-Aspirin is a large randomised clinical trial which is taking place in the UK, Republic of Ireland and India. it will recruit 11,000 participants to help find out whether regular aspirin use after treatment for an early stage cancer can prevent the cancer from returning and preventing deaths. 

ROSCO
Principal Investigator: Mr Tahir Masudi
Sponsor: University of Birmingham
ROSCO is a randomised stage III, stratified biomarker trial of neo-adjuvant 5-Florouracil, Epirubicin and Cyclophosphamide vs Docetaxal and Cyclophosphamide chemotherapy.